Background: Branch retinal vein occlusion is a frequent cause of visual loss with currently insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin ®) treatment in patients ...

Thorough systemic evaluation should be performed in young patients with retinal vascular occlusion. Retinal opacification in a branch retinal artery occlusion resolves over 4–6 weeks with development ...

So we call it a central vein occlusion because it impacts the entire retina. Or you can have something called a branch retinal vein occlusion. And what that means is that you've only impacted a ...

Vascular occlusion of a retinal artery ... and compression by an atherosclerotic central retinal artery are suggested mechanisms of central retinal vein obstruction (CRVO). Hypercoagulable states, ...

Bevacizumab is under clinical development by Outlook Therapeutics and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for Branch Retinal Vein ...

601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for ...

stanford.edu Retinal vein occlusion is the second-leading cause of vision loss by retinal vascular disease. Subthreshold micropulse laser therapy (SLT) is safer than conventional laser ...

Bilateral cases of branch retinal vein occlusions (BRVO) are infrequent and often related to systemic disease. A 72-year-old man with biochemical recurrence of prostate cancer was referred for ...

such as branch retinal artery occlusion, ocular ischemic syndrome, central retinal vein occlusion, and proliferative diabetic retinopathy; and (3) CRAO from an iatrogenic cause. Details of the patient ...